EMA plans COVID-19 vaccine safety monitoring

21 July 2020
europe_flag_eu_big

A new project from the European Medicines Agency (EMA) has been established to monitor the efficacy and safety of COVID-19 treatments and vaccines in everyday clinical practice.

The EMA says it has also reached agreements with academic and private partners to boost efforts to ensure that vaccines are effectively monitored from the moment they are used following authorization.

Utrecht University and the University Medical Center Utrecht are helping to coordinate the CONSIGN project, collecting data and analyzing existing data sources such as electronic health records.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology